Amedisys Inc (NASDAQ:AMED) Shares Bought by Northwestern Mutual Investment Management Company LLC

Northwestern Mutual Investment Management Company LLC grew its stake in shares of Amedisys Inc (NASDAQ:AMED) by 21.6% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 11,204 shares of the health services provider’s stock after purchasing an additional 1,991 shares during the quarter. Northwestern Mutual Investment Management Company LLC’s holdings in Amedisys were worth $2,056,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently modified their holdings of the business. AGF Investments Inc. lifted its stake in shares of Amedisys by 60.0% during the first quarter. AGF Investments Inc. now owns 40,000 shares of the health services provider’s stock worth $7,342,000 after purchasing an additional 15,000 shares in the last quarter. ETRADE Capital Management LLC increased its position in shares of Amedisys by 3.3% during the first quarter. ETRADE Capital Management LLC now owns 8,403 shares of the health services provider’s stock worth $1,543,000 after acquiring an additional 266 shares during the last quarter. PNC Financial Services Group Inc. increased its position in shares of Amedisys by 49.6% during the first quarter. PNC Financial Services Group Inc. now owns 7,083 shares of the health services provider’s stock worth $1,301,000 after acquiring an additional 2,348 shares during the last quarter. Swiss National Bank increased its position in shares of Amedisys by 1.8% during the first quarter. Swiss National Bank now owns 62,600 shares of the health services provider’s stock worth $11,490,000 after acquiring an additional 1,100 shares during the last quarter. Finally, First Allied Advisory Services Inc. increased its position in shares of Amedisys by 51.4% during the first quarter. First Allied Advisory Services Inc. now owns 1,974 shares of the health services provider’s stock worth $362,000 after acquiring an additional 670 shares during the last quarter. Institutional investors own 88.75% of the company’s stock.

In other Amedisys news, Director Vickie L. Capps purchased 1,000 shares of the company’s stock in a transaction on Tuesday, February 25th. The stock was acquired at an average cost of $187.00 per share, for a total transaction of $187,000.00. Following the purchase, the director now directly owns 1,780 shares of the company’s stock, valued at approximately $332,860. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider David L. Kemmerly sold 23,437 shares of the company’s stock in a transaction that occurred on Tuesday, May 5th. The stock was sold at an average price of $175.32, for a total value of $4,108,974.84. The disclosure for this sale can be found here. Over the last three months, insiders purchased 4,000 shares of company stock valued at $635,950 and sold 36,053 shares valued at $6,336,849. Corporate insiders own 2.90% of the company’s stock.

Amedisys stock opened at $192.01 on Friday. The firm has a 50 day moving average of $186.56 and a 200 day moving average of $174.52. The firm has a market capitalization of $6.21 billion, a price-to-earnings ratio of 50.00, a P/E/G ratio of 2.98 and a beta of 0.89. Amedisys Inc has a 12-month low of $107.17 and a 12-month high of $218.44. The company has a current ratio of 1.48, a quick ratio of 1.48 and a debt-to-equity ratio of 0.64.

Amedisys (NASDAQ:AMED) last released its earnings results on Wednesday, May 6th. The health services provider reported $1.05 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.97 by $0.08. The company had revenue of $491.70 million during the quarter, compared to analyst estimates of $507.45 million. Amedisys had a net margin of 6.43% and a return on equity of 23.09%. The firm’s quarterly revenue was up 5.3% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.11 EPS. On average, analysts predict that Amedisys Inc will post 4.61 EPS for the current year.

A number of analysts have recently issued reports on AMED shares. Zacks Investment Research raised Amedisys from a “hold” rating to a “buy” rating and set a $193.00 target price on the stock in a research report on Friday, May 1st. SunTrust Banks upped their price target on shares of Amedisys from $225.00 to $240.00 and gave the stock a “buy” rating in a research note on Thursday. Benchmark cut shares of Amedisys from a “buy” rating to a “hold” rating in a research note on Thursday, May 7th. BidaskClub upgraded shares of Amedisys from a “buy” rating to a “strong-buy” rating in a research note on Saturday, March 14th. Finally, Oppenheimer reiterated a “buy” rating and issued a $215.00 price target on shares of Amedisys in a research note on Monday, April 27th. Six investment analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $191.20.

About Amedisys

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, social workers, and aides for its patients to complete their important personal tasks.

Recommended Story: Cost of Equity

Institutional Ownership by Quarter for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.